We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights Alphabet, Mastercard, AbbVie, Perma-Pipe and ImmuCell
Read MoreHide Full Article
For Immediate Release
Chicago, IL – September 29, 2026 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Alphabet Inc. (GOOGL - Free Report) , Mastercard Inc. (MA - Free Report) , AbbVie Inc. (ABBV - Free Report) , Perma-Pipe International Holdings, Inc. (PPIH - Free Report) and ImmuCell Corp. (ICCC - Free Report) .
Here are highlights from Monday’s Analyst Blog:
Top Research Reports for Alphabet, Mastercard and AbbVie
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Alphabet Inc., Mastercard Inc. and AbbVie Inc., as well as two micro-cap stocks Perma-Pipe International Holdings, Inc. and ImmuCell Corp. The Zacks microcap research is unique as our research content on these small and under-the-radar companies is the only research of its type in the country.
These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
The daily 'Ahead of Wall Street' article is a must-read for all investors who would like to be ready for that day's trading action. The article comes out before the market opens, attempting to make sense of that morning's economic releases and how they will affect that day's market action. You can read this article for free on our home page and can actually sign up there to get an email notification as this article comes out each morning.
Alphabet’s shares have outperformed the Zacks Internet - Services industry over the year-to-date period (+10.1% vs. +8.4%). The company’s AI-led product cycle is strengthening Search, Cloud and subscriptions, while broader enterprise adoption and flexible infrastructure models support long-term monetization.
Search and YouTube remain durable cash generators, and Cloud is deepening customer relationships across AI, data and security. Alphabet’s differentiated silicon and long-term infrastructure contracts may improve returns on AI investment. These positives are offset by rising capital intensity, weaker free cash flow and a larger debt load.
Advertising concentration, legal remedies and intense AI competition also create uncertainty around margins and returns. Higher infrastructure spending could weigh on near-term cash generation. With stronger Cloud economics balanced by investment and regulatory risk, the shares present an even risk-reward profile.
Shares of Mastercard have declined -0.1% over the year-to-date period against the Zacks Financial Transaction Services industry’s decline of -11.3%. The company’s rising rebates and incentives signal greater competitive pricing pressure, while merchant litigation and alternative payment rails could weaken network economics. A premium valuation leaves less room for execution setbacks. As such, we have a Neutral view.
Nevertheless, Mastercard benefits from the secular shift toward electronic payments, supported by a scalable, asset-light model that can convert rising transaction volumes into attractive incremental economics. Resilient consumer spending and cross-border demand provide revenue visibility, while growing value-added services broaden the earnings base beyond core payment processing.
Strategic partnerships, acquisitions and expansion into emerging payment flows further extend its addressable market. Strong cash generation also supports continued reinvestment, acquisitions and shareholder returns.
AbbVie’s shares have outperformed the Zacks Large Cap Pharmaceuticals industry over the year-to-date period (+18.4% vs. +15.3%). The company has successfully navigated Humira's loss of exclusivity by launching two other successful immunology medicines, Skyrizi and Rinvoq, which are performing extremely well, bolstered by approvals in new indications, and should support top-line growth in the next few years.
AbbVie’s neuroscience portfolio is also rapidly expanding and contributing significantly to top-line growth. AbbVie boasts a robust pipeline and expects key data readouts, regulatory submissions, and approvals over the next few months.
AbbVie has been on an acquisition spree in the past couple of years to bolster its early-stage pipeline that should drive long-term growth. However, the company faces several headwinds like Humira LOE impact, slowing oncology sales and continued macro headwinds for Aesthetics.
Shares of Perma-Pipe International have gained +4.5% over the year-to-date period against the Zacks Steel - Pipe and Tube industry’s gain of +39.8%. This microcap company with a market capitalization of $260.11 million sees its backlog reach $143.2 million, with 40-50% expected to convert to revenue within 12 months. Second-quarter bookings of more than $67 million exceeded quarterly sales. Growth is being supported across MENA, Canada, leak detection and the Ohio facility, reducing reliance on a single market.
Capacity ramps in Ohio and Qatar could improve fixed-cost absorption as utilization rises, while leak-detection bookings had already reached about 80% of the full-year target by the second quarter. First-half operating cash flow also improved to $13.3 million.
Risks include gross-margin pressure from start-up costs, inflation, shipping expenses and project mix, along with higher customer concentration and receivable exposure. Foreign-exchange volatility, geopolitical tensions and trade-related costs could also create variability in results. The stock’s valuation is below peers on EV/sales basis.
ImmuCell’s shares have outperformed the Zacks Medical - Products industry over the year-to-date period (+61.4% vs. -20.8%). This microcap company with a market capitalization of $90.14 million has its investment case supported by strengthening demand for its First Defense platform, particularly Tri-Shield, alongside rising producer adoption and market penetration. Manufacturing expansion should ease capacity constraints, shorten processing times and support scalable long-term growth.
Yield improvements, better colostrum sourcing and tighter process discipline offer a path to stronger manufacturing economics. The company’s sharper focus on First Defense is also improving resource allocation by redirecting spending and existing infrastructure toward its core commercial franchise.
Improving cash generation provides greater flexibility to fund capacity investments with less reliance on external financing. Meanwhile, continued U.S. commercial expansion offers additional growth runway, while international markets remain a longer-term opportunity.
Free: Instant Access to Zacks' Market-Crushing Strategies
Since 2000, our top stock-picking strategies have blown away the S&P's +7.7% average gain per year. Amazingly, they soared with average gains of +48.4%, +50.2% and +56.7% per year.
Today you can tap into those powerful strategies – and the high-potential stocks they uncover – free. No strings attached.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
View the Zacks #1 Rank List
Image: Bigstock
The Zacks Analyst Blog Highlights Alphabet, Mastercard, AbbVie, Perma-Pipe and ImmuCell
For Immediate Release
Chicago, IL – September 29, 2026 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Alphabet Inc. (GOOGL - Free Report) , Mastercard Inc. (MA - Free Report) , AbbVie Inc. (ABBV - Free Report) , Perma-Pipe International Holdings, Inc. (PPIH - Free Report) and ImmuCell Corp. (ICCC - Free Report) .
Here are highlights from Monday’s Analyst Blog:
Top Research Reports for Alphabet, Mastercard and AbbVie
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Alphabet Inc., Mastercard Inc. and AbbVie Inc., as well as two micro-cap stocks Perma-Pipe International Holdings, Inc. and ImmuCell Corp. The Zacks microcap research is unique as our research content on these small and under-the-radar companies is the only research of its type in the country.
These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Ahead of Wall Street
The daily 'Ahead of Wall Street' article is a must-read for all investors who would like to be ready for that day's trading action. The article comes out before the market opens, attempting to make sense of that morning's economic releases and how they will affect that day's market action. You can read this article for free on our home page and can actually sign up there to get an email notification as this article comes out each morning.
You can read today's AWS here >>> Big Week of Jobs & Inflation Data, Micron Earnings
Today's Featured Research Reports
Alphabet’s shares have outperformed the Zacks Internet - Services industry over the year-to-date period (+10.1% vs. +8.4%). The company’s AI-led product cycle is strengthening Search, Cloud and subscriptions, while broader enterprise adoption and flexible infrastructure models support long-term monetization.
Search and YouTube remain durable cash generators, and Cloud is deepening customer relationships across AI, data and security. Alphabet’s differentiated silicon and long-term infrastructure contracts may improve returns on AI investment. These positives are offset by rising capital intensity, weaker free cash flow and a larger debt load.
Advertising concentration, legal remedies and intense AI competition also create uncertainty around margins and returns. Higher infrastructure spending could weigh on near-term cash generation. With stronger Cloud economics balanced by investment and regulatory risk, the shares present an even risk-reward profile.
(You can read the full research report on Alphabet here >>>)
Shares of Mastercard have declined -0.1% over the year-to-date period against the Zacks Financial Transaction Services industry’s decline of -11.3%. The company’s rising rebates and incentives signal greater competitive pricing pressure, while merchant litigation and alternative payment rails could weaken network economics. A premium valuation leaves less room for execution setbacks. As such, we have a Neutral view.
Nevertheless, Mastercard benefits from the secular shift toward electronic payments, supported by a scalable, asset-light model that can convert rising transaction volumes into attractive incremental economics. Resilient consumer spending and cross-border demand provide revenue visibility, while growing value-added services broaden the earnings base beyond core payment processing.
Strategic partnerships, acquisitions and expansion into emerging payment flows further extend its addressable market. Strong cash generation also supports continued reinvestment, acquisitions and shareholder returns.
(You can read the full research report on Mastercard here >>>)
AbbVie’s shares have outperformed the Zacks Large Cap Pharmaceuticals industry over the year-to-date period (+18.4% vs. +15.3%). The company has successfully navigated Humira's loss of exclusivity by launching two other successful immunology medicines, Skyrizi and Rinvoq, which are performing extremely well, bolstered by approvals in new indications, and should support top-line growth in the next few years.
AbbVie’s neuroscience portfolio is also rapidly expanding and contributing significantly to top-line growth. AbbVie boasts a robust pipeline and expects key data readouts, regulatory submissions, and approvals over the next few months.
AbbVie has been on an acquisition spree in the past couple of years to bolster its early-stage pipeline that should drive long-term growth. However, the company faces several headwinds like Humira LOE impact, slowing oncology sales and continued macro headwinds for Aesthetics.
(You can read the full research report on AbbVie here >>>)
Shares of Perma-Pipe International have gained +4.5% over the year-to-date period against the Zacks Steel - Pipe and Tube industry’s gain of +39.8%. This microcap company with a market capitalization of $260.11 million sees its backlog reach $143.2 million, with 40-50% expected to convert to revenue within 12 months. Second-quarter bookings of more than $67 million exceeded quarterly sales. Growth is being supported across MENA, Canada, leak detection and the Ohio facility, reducing reliance on a single market.
Capacity ramps in Ohio and Qatar could improve fixed-cost absorption as utilization rises, while leak-detection bookings had already reached about 80% of the full-year target by the second quarter. First-half operating cash flow also improved to $13.3 million.
Risks include gross-margin pressure from start-up costs, inflation, shipping expenses and project mix, along with higher customer concentration and receivable exposure. Foreign-exchange volatility, geopolitical tensions and trade-related costs could also create variability in results. The stock’s valuation is below peers on EV/sales basis.
(You can read the full research report on Perma-Pipe International here >>>)
ImmuCell’s shares have outperformed the Zacks Medical - Products industry over the year-to-date period (+61.4% vs. -20.8%). This microcap company with a market capitalization of $90.14 million has its investment case supported by strengthening demand for its First Defense platform, particularly Tri-Shield, alongside rising producer adoption and market penetration. Manufacturing expansion should ease capacity constraints, shorten processing times and support scalable long-term growth.
Yield improvements, better colostrum sourcing and tighter process discipline offer a path to stronger manufacturing economics. The company’s sharper focus on First Defense is also improving resource allocation by redirecting spending and existing infrastructure toward its core commercial franchise.
Improving cash generation provides greater flexibility to fund capacity investments with less reliance on external financing. Meanwhile, continued U.S. commercial expansion offers additional growth runway, while international markets remain a longer-term opportunity.
(You can read the full research report on ImmuCell here >>>)
Free: Instant Access to Zacks' Market-Crushing Strategies
Since 2000, our top stock-picking strategies have blown away the S&P's +7.7% average gain per year. Amazingly, they soared with average gains of +48.4%, +50.2% and +56.7% per year.
Today you can tap into those powerful strategies – and the high-potential stocks they uncover – free. No strings attached.
Get all the details here >>
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.